Turalio FDA approval : Daiichi Sankyo has secured approval for its CSF1R inhibitor Turalio (pexidartinib) from the US Food and Drug Administration (FDA) for the treatment of tenosynovial giant cell tumor (TGCT). The FDA approval of Turalio is for the treatment of adult patients having symptomatic tenosynovial giant cell tumor associated with severe morbidity or […]
Continue reading …MONARCH 2 clinical trial results : Verzenio, fulvestrant combo improves overall survival in metastatic breast cancer
July 31, 2019 No Comment
MONARCH 2 clinical trial results : Eli Lilly and Company (Lilly) said that Verzenio (abemaciclib) in combination with fulvestrant delivered a statistically significant improvement in overall survival in the phase 3 MONARCH 2 clinical trial held for a type of metastatic breast cancer. The US pharma giant said that the MONARCH 2 clinical trial results […]
Continue reading …
Libtayo EMA approval : The European Commission has given conditional approval for Libtayo (cemiplimab) for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), which is one of the most commonly diagnosed skin cancers. Libtayo, which is a fully-human monoclonal antibody targeting the immune checkpoint receptor programmed cell death […]
Continue reading …
Boehringer Ingelheim acquisition of AMAL Therapeutics : German pharma company Boehringer Ingelheim has acquired Swiss biotech company AMAL Therapeutics for up to EUR325 million, as per the latest pharma acquisition news. AMAL Therapeutics, which was spun out from the University of Geneva in 2012, is focused on cancer immunotherapy and is engaged in advancing therapeutic […]
Continue reading …
Merck acquisition of Peloton : Pharma giant Merck is set to acquire US biopharma company Peloton Therapeutics in a deal worth up to $2.2 billion, according to pharma acquisition news. Based in Texas, Peloton Therapeutics is a clinical-stage company engaged in the development of small molecule therapeutics that target hypoxia-inducible factor-2α (HIF-2α) for the treatment […]
Continue reading …Pixuvri EMA approval : Servier NHL drug secures standard marketing authorization in Europe
June 13, 2019 No Comment
Pixuvri EMA approval : French pharma company Servier has secured full approval for Pixuvri (pixantrone) from the European Commission (EC) as monotherapy for aggressive non-Hodgkin B-cell lymphoma (NHL) in adult patients whose condition is multiply relapsed or refractory. Pixuvri EMA approval Since 2012, Pixantrone has been available in Europe to patients following conditional approval, which […]
Continue reading …
Lynparza EMA approval : Pharma giants AstraZeneca and MSD have secured an expansion of the European Medical Agency’s (EMA) approval for their poly ADP-ribose polymerase (PARP) inhibitor Lynparza (olaparib) to be used for the treatment of a type of advanced breast cancer. The expanded Lynparza EMA approval allows the PARP inhibitor to be used as […]
Continue reading …
Kadcyla FDA approval : Roche subsidiary Genentech has secured approval from the US Food and Drug Administration (FDA) for its breast cancer drug Kadcyla (ado-trastuzumab emtansine) for post-surgery treatment of HER2-positive early breast cancer (EBC) in patients with residual invasive disease who were subjected to before surgery taxane and Herceptin (trastuzumab)-based treatment. The Kadcyla FDA […]
Continue reading …Ibrance FDA approval : Pfizer breast cancer drug approved for metastatic breast cancer in men
April 17, 2019 No Comment
New Ibrance FDA approval : The US Food and Drug Administration (FDA) has extended the approval of Pfizer breast cancer drug Ibrance (palbociclib) to cover the treatment of hormone receptor positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients. Latest Ibrance FDA approval Under the new indication approved […]
Continue reading …
Pharma industry news : Arch Oncology, a California-based clinical-stage immune-oncology company, has raised a funding of $50 million in a Series B financing round. The immune-oncology company is engaged in the discovery and development of anti-CD47 antibody therapies. The new capital will enable Arch Oncology to advance the ongoing phase 1 clinical trial of its […]
Continue reading …
Business News Today
- AFC joins Brahms Oil Refineries to advance Brahms refinery project, Guinea
- Precision oncology company Black Diamond Therapeutics raises $85m
- FLIR Systems bags US Army contract for Kobra robot under CRS-H program
- Vår Energi selects Capgemini to deliver digital transformation
- AstraZeneca taps into Gatehouse Bio’s sRNAlytics AI platform for drug discovery
- BJ’s Wholesale Club launches Wellsley Farms premium spirits
- Soligenix all set to begin FLASH clinical trial for SGX301 in CTCL
- Tor field : ConocoPhillips gets PSA nod for production drilling
- Miami Grill seeks out franchise partners in Jacksonville, Florida
- GE Healthcare unveils Serena Bright mammography solution for biopsy
